160 related articles for article (PubMed ID: 33886085)
1. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
Umezawa Y; Asahina A; Imafuku S; Tada Y; Sano S; Morita A; Sakurai S; Hoshii N; Tilt N; Nakagawa H
Dermatol Ther (Heidelb); 2021 Jun; 11(3):943-960. PubMed ID: 33886085
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.
Umezawa Y; Sakurai S; Hoshii N; Nakagawa H;
Dermatol Ther (Heidelb); 2021 Apr; 11(2):513-528. PubMed ID: 33606269
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.
Imafuku S; Tada Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jan; 12(1):121-135. PubMed ID: 34826124
[TBL] [Abstract][Full Text] [Related]
4. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Warren RB; Lebwohl M; Sofen H; Piguet V; Augustin M; Brock F; C Arendt ; Fierens F; Blauvelt A
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2398-2408. PubMed ID: 34192387
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
Okubo Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1397-1415. PubMed ID: 35622315
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Gordon KB; Warren RB; Gottlieb AB; Blauvelt A; Thaçi D; Leonardi C; Poulin Y; Boehnlein M; Brock F; Ecoffet C; Reich K
Br J Dermatol; 2021 Apr; 184(4):652-662. PubMed ID: 32652544
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
Gisondi P; Gottlieb AB; Elewski B; Augustin M; McBride S; Tsai TF; de la Loge C; Fierens F; López Pinto JM; Tilt N; Lebwohl M
Dermatol Ther (Heidelb); 2023 Jan; 13(1):315-328. PubMed ID: 36509889
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Korge B; Vanhooteghem O; Lynde CW; Machovcova A; Perrussel M; Lazaridou E; Marasca C; Sarro DV; Pousa ID; Fierens F; Williams P; Shimizu S; Heidbrede T; Warren RB
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38937404
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
[TBL] [Abstract][Full Text] [Related]
11. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Blauvelt A; Paul C; van de Kerkhof P; Warren RB; Gottlieb AB; Langley RG; Brock F; Arendt C; Boehnlein M; Lebwohl M; Reich K
Br J Dermatol; 2021 Apr; 184(4):640-651. PubMed ID: 32531798
[TBL] [Abstract][Full Text] [Related]
13. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.
van der Heijde D; Deodhar A; FitzGerald O; Fleischmann R; Gladman D; Gottlieb AB; Hoepken B; Bauer L; Irvin-Sellers O; Khraishi M; Peterson L; Turkiewicz A; Wollenhaupt J; Mease PJ
RMD Open; 2018; 4(1):e000582. PubMed ID: 29556416
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M; Dogan S
Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
17. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Ruiz AN; Alberola FT; Aceituno S;
Farm Hosp; 2024; 48(2):T51-T56. PubMed ID: 38148255
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
Vender RB; Lynde CW
J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
[TBL] [Abstract][Full Text] [Related]
20. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
